1. Pui, C. H., Relling, M. V., & Downing, J. R. (2004). Acute lymphoblastic leukemia. The New England Journal of Medicine, 350, 1535–1548.
2. Larson, R. A., Dodge, R. K., Burns, C. P., Lee, E. J., Stone, R. M., Schulman, P., et al. (1995). A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood, 85, 2025–2037.
3. Larson, R. A., Dodge, R. K., Linker, C. A., Stone, R. M., Powell, B. L., Lee, E. J., et al. (1998). A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood, 92, 1556–1564.
4. Stock, W., Johnson, J., Yu, D., Bennett, D., Sher, D., Stone, R. M., et al. (2005). Daunorubicin dose intensification during treatment of adult Acute Lymphoblastic Leukemia (ALL): Final results from Cancer and Leukemia Group B Study 19802 [abstract]. Blood, 106, 521a.
5. Kantarjian, H., Thomas, D., O’Brien, S., Cortes, J., Giles, F., Jeha, S., et al. (2004). Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer, 101, 2788–2801.